Treatment of endometriosis with gestrinone (R-2323), a synthetic antiestrogen, antiprogesterone.
Twenty patients with endometriosis diagnosed by laparoscopy were treated with the antiestrogen, antiprogesterone gestrinone (R-2323) for 6 to 8 months. The drug was administered in a dose of 5 mg twice weekly. According to the American Fertility Society's classification of endometriosis, five patients were classified as having mild (Stage I), eight as having moderate (Stage II), and seven as having severe endometriosis (Stage III). All patients became amenorrheic at the end of the second month of treatment, and symptomless at the end of the third month. Of nine women who had the potential and the desire to conceive, three conceived within 3 months after termination of treatment. Two more became pregnant within 1 year, and another, 14 months after termination of treatment. Five pregnancies progressed to term. One patient aborted. Two of the three women who did not conceive had subfertile husbands. Major side effects recorded were seborrhea and acne, which subsided after discontinuation of therapy. Treatment of endometriosis with gestrinone offers the advantage of effective clearing of lesions with relatively low dosage and frees the patient from the daily administration of drugs required by similar conservative hormonal therapies.
D000152:Acne Vulgaris / Q000139:chemically induced; D000328:Adult; D012628:Dermatitis, Seborrheic / Q000139:chemically induced; D004715:Endometriosis / Q000145:classification / Q000188:drug therapy*; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D005867:Gestrinone / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009651:Norpregnatrienes / Q000627:therapeutic use*; D011247:Pregnancy; D011374:Progesterone / Q000037:antagonists & inhibitors*
D004965:Estrogen Antagonists; D009651:Norpregnatrienes; D005867:Gestrinone; D011374:Progesterone